| Jun 13 |
Replimune Announces $100 Million Private Placement Financing
|
| Jun 7 |
Replimune (REPL) Gains on Positive Data From Melanoma Study
|
| Jun 7 |
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
|
| Jun 6 |
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
|
| Jun 6 |
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
|
| Jun 6 |
Replimune up 30% on results for RP1 combo in melanoma
|
| Jun 6 |
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
|
| Jun 3 |
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
| May 23 |
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
| May 22 |
Replimune: Continuing To Justify The Bear Thesis (For Now)
|
